Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 2137-2154 |
| Number of pages | 18 |
| Journal | Nanomedicine |
| Volume | 16 |
| Issue number | 24 |
| DOIs | |
| State | Published - Sep 17 2021 |
Bibliographical note
Publisher Copyright:© 2021 Future Medicine Ltd.
Funding
This research is a part of PhD thesis (no. 129) and supported by Research Vice-Chancellor of Tabriz University of Medical Sciences (no. 129) and the Research Center for Pharmaceutical Nanotechnology at Tabriz University of Medical Sciences. Y Omidi is a member of the Nanomedicine Editorial Board. They were not involved in any editorial decisions related to the publication of this article, and all author details were blinded to the article’s peer reviewers as per the journal’s double-blind peer review policy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
ASJC Scopus Subject Areas
- Bioengineering
- Medicine (miscellaneous)
- Biomedical Engineering
- General Materials Science
Keywords
- breast cancer
- chemotherapy
- d-1-methyl-tryptophan
- immunotherapy
- indoleamine-2, 3-dioxygenase
- targeted therapy
- theranostics
Disciplines
- Biomedical Engineering and Bioengineering
- Materials Science and Engineering
- Medicine and Health Sciences
Fingerprint
Dive into the research topics of 'Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS